Dr Reddy’s Q1 results: Net profit declines 69% to ₹4,435 crore; revenue down over 5%; check key numbers

Shares of Dr Reddy’s closed 1.9% lower at ₹1,182.80 after the market hours on Wednesday, compared to ₹1,206 at the previous stock market close. The pharma company filed its Q1 earnings report after market hours on July 22.

NSE filings showed that the Dr Reddy's Laboratories’ net profit (attributable to the owners of the company) declined 69% to ₹4,435 crore in the April to June quarter results for the financial year 2026-27, compared year-on-year (YoY) with ₹14,178 crore in the same period a year ago.

The pharma company’s overall revenue from core operations dropped 5.5% to ₹8,070.5 crore in the first quarter results, compared to ₹8,545.2 crore in the same quarter of the previous financial year.

The consolidated financial statements also showed that the overall expenses for the pharma major advanced 17% to ₹4,316 crore, from ₹3,682 crore in the same quarter of the previous financial year.

Segmental revenues

Pharmaceutical company Dr Reddy’s segmental revenue data showed that the firm’s global generics revenues declined 4.7% to ₹7,199.3 crore in the April to June quarter, compared year-on-year with ₹7,562 crore in the same period a year ago.

Global generics revenues account for the majority of the company’s revenue from core operations. Hence a fall in the segment revenues in turn weighs down the financial performance of the firm.

Dr Reddy’s revenues from pharmaceutical services and active ingredients business advanced 8.4% to ₹1,052 crore in the June quarter, from ₹970 crore in the same period a year earlier.

How have Dr Reddy’s shares performed?

Dr Reddy shares have gained more than 9% in the last five years, and have risen more than 11% in the last three years, according to NSE data. However the company shares have lost 5% in the past one year period.

On a year-to-date (YTD) basis, Dr Reddy stock has lost 6%, and has dropped 8.5% in the last one month period. The exchange data also showed that the company shares were trading 4% lower in the last five market sessions.

Dr Reddy shares surged to a 52-week high of ₹1,414.90 on June 29, 2026, while the 52-week low was at ₹1,148.40 on January 21, 2026. The company has a market capitalisation (m-cap) of ₹98,483 as of the stock market close on Wednesday, July 22, 2026.